Thuy-Linh Nguyen
Family Medicine · Honolulu, HINPI 1730642034
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,402, 7.9 times the $432 reported in 2022. Among family medicine clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $47.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$2K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$986
- Indivior Inc.$696
- Otsuka America Pharmaceutical, Inc.$684
- plus $2K from 19 others
What the payments were for
- Food & beverage$9,156100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 45 | $2,090 |
| Gilead | 49 | $1,581 |
| AbbVie | 17 | $1,033 |
| Teva Pharmaceuticals USA, Inc. | 23 | $986 |
| Indivior Inc. | 11 | $696 |
| Otsuka America Pharmaceutical, Inc. | 15 | $684 |
| Alkermes, Inc. | 7 | $628 |
| E.r. Squibb & Sons, L.L.C. | 4 | $217 |
| Sanofi-aventis U.S. LLC | 1 | $146 |
| Novo Nordisk | 2 | $134 |
| Insulet Corporation | 1 | $125 |
| Merck | 1 | $125 |
| Amgen | 1 | $122 |
| Abbott | 1 | $116 |
| Lundbeck LLC | 4 | $86 |
| Medtronic | 1 | $77 |
| GSK | 3 | $74 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $55 |
| Madrigal Pharmaceuticals | 1 | $46 |
| Boehringer Ingelheim | 1 | $32 |
| EMD Serono, Inc. | 1 | $31 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $17 |
| Pfizer | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,156 in reported general payments places this provider in the 95th percentile of 376 family medicine providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $52,146 |
| OzempicSemaglutide | 33 | $35,091 |
| JardianceEmpagliflozin | 15 | $17,751 |
| Estradiol | 21 | $2,143 |
| Potassium Chloride | 13 | $1,096 |
| Atorvastatin Calcium | 76 | $1,042 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $963 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $704 |
| ValacyclovirValacyclovir Hcl | 13 | $652 |
| Duloxetine Hcl | 35 | $527 |
| Promethazine Hcl | 39 | $506 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $338 |
| Fluticasone Propionate | 16 | $318 |
| Omeprazole | 16 | $297 |
| Metoprolol Succinate | 28 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $1,581 | $52,14613 claims |
| Novo NordiskOzempic | $134 | $35,09133 claims |
| Boehringer IngelheimJardiance | $32 | $17,75115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 376 family medicine providers in Hawaii.
Other family medicine in Honolulu
- Vicente RamoHonolulu$34K
- Choon YeoHonolulu$20K
- Gavino VinzonsHonolulu$15K
- Owen NishikawaHonolulu$7K
- Kelsey FinnHonolulu$5K
- Curtis Takemoto GentileHonolulu$4K
- Krishanna Takemoto-GentileHonolulu$4K
- Yoichi SomaHonolulu$4K
- Loan-Thy DangHonolulu$3K
- Ronnie OtienoHonolulu$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.